NEW YORK (GenomeWeb News) – Gene modification firm Transposagen Biopharmaceuticals said on Friday that it received $4.3 million in grants and investments to further develop its DNA modification technology.

The Lexington, Ky.-based firm said that it received a Small Business Innovation Research grant of almost $2.0 million from the National Institutes of Health's Office of the Director, and a $1.0 million grant from the Kentucky Cabinet for Economic Development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.